These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1914362)

  • 1. Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.
    Hartman NR; Yarchoan R; Pluda JM; Thomas RV; Wyvill KM; Flora KP; Broder S; Johns DG
    Clin Pharmacol Ther; 1991 Sep; 50(3):278-85. PubMed ID: 1914362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.
    Hartman NR; Yarchoan R; Pluda JM; Thomas RV; Marczyk KS; Broder S; Johns DG
    Clin Pharmacol Ther; 1990 May; 47(5):647-54. PubMed ID: 2111751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS.
    Burger D; Meenhorst P; Mulder J; Henrichs J; Frissen J; Kroon F; ten Napel C; Koks K; Bult A; Beijnen J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):163-8. PubMed ID: 7552480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.
    Knupp CA; Shyu WC; Dolin R; Valentine FT; McLaren C; Martin RR; Pittman KA; Barbhaiya RH
    Clin Pharmacol Ther; 1991 May; 49(5):523-35. PubMed ID: 1903100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials.
    Drusano GL; Yuen GJ; Morse G; Cooley TP; Seidlin M; Lambert JS; Liebman HA; Valentine FT; Dolin R
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1280-3. PubMed ID: 1416828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Didanosine.
    Shelton MJ; O'Donnell AM; Morse GD
    Ann Pharmacother; 1992 May; 26(5):660-70. PubMed ID: 1350471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphatic targeting of anti-HIV nucleosides: distribution of 2',3'-dideoxyinosine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug in mice.
    Manouilov KK; Xu ZS; Boudinot FD; Schinazi RF; Chu CK
    Antiviral Res; 1997 May; 34(3):91-9. PubMed ID: 9191016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral absorption of anti-aids nucleoside analogues: 3. Regional absorption and in vivo permeability of 2',3'-dideoxyinosine in an intestinal-vascular access port (IVAP) dog model.
    Sinko PJ; Sutyak JP; Leesman GD; Hu P; Makhey VD; Yu H; Smith CL
    Biopharm Drug Dispos; 1997 Nov; 18(8):697-710. PubMed ID: 9373726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of didanosine from enteric-coated, sustained-release bioadhesive formulation.
    Deshmukh D; Ravis WR; Betageri GV
    Drug Deliv; 2003; 10(1):47-50. PubMed ID: 12554364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopharmaceutics of didanosine in humans and in a model for acid-labile drugs, the pentagastrin-pretreated dog.
    Knupp CA; Shyu WC; Morgenthien EA; Lee JS; Barbhaiya RH
    Pharm Res; 1993 Aug; 10(8):1157-64. PubMed ID: 8415401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
    Lambert JS; Seidlin M; Reichman RC; Plank CS; Laverty M; Morse GD; Knupp C; McLaren C; Pettinelli C; Valentine FT
    N Engl J Med; 1990 May; 322(19):1333-40. PubMed ID: 2139173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex.
    Pai SM; Shukla UA; Grasela TH; Knupp CA; Dolin R; Valentine FT; McLaren C; Liebman HA; Martin RR; Pittman KA
    J Clin Pharmacol; 1992 Mar; 32(3):242-7. PubMed ID: 1564128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of dideoxyinosine in pigtailed macaques (Macaca nemestrina) after intravenous and subcutaneous administration.
    Ravasco RJ; Unadkat JD; Tsai CC; Nosbisch C
    J Acquir Immune Defic Syndr (1988); 1992 Oct; 5(10):1016-8. PubMed ID: 1453316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus.
    Knupp CA; Graziano FM; Dixon RM; Barbhaiya RH
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2075-9. PubMed ID: 1444287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats.
    Anderson BD; Morgan ME; Singhal D
    Pharm Res; 1995 Aug; 12(8):1126-33. PubMed ID: 7494823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption of 2',3'-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectum.
    Bramer SL; Wientjes MG; Au JL
    Pharm Res; 1993 May; 10(5):763-70. PubMed ID: 8321843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive absorption of 2',3'-dideoxyinosine by intratracheal administration in rats.
    Gao X; Wientjes MG; Au JL
    Pharm Res; 1995 Dec; 12(12):1901-6. PubMed ID: 8786964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percutaneous absorption of 2',3'-dideoxyinosine in rats.
    Mukherji E; Millenbaugh NJ; Au JL
    Pharm Res; 1994 Jun; 11(6):809-15. PubMed ID: 7937518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prodrugs of 2',3'-dideoxyinosine (DDI): improved oral bioavailability via hydrophobic esters.
    Kawaguchi T; Hasegawa T; Seki T; Juni K; Morimoto Y; Miyakawa A; Saneyoshi M
    Chem Pharm Bull (Tokyo); 1992 May; 40(5):1338-40. PubMed ID: 1394659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.
    Balis FM; Pizzo PA; Butler KM; Hawkins ME; Brouwers P; Husson RN; Jacobsen F; Blaney SM; Gress J; Jarosinski P
    J Infect Dis; 1992 Jan; 165(1):99-104. PubMed ID: 1727902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.